ATE217532T1 - Eine didemnin verbindung enthaltende pharmazeutische formulierung - Google Patents

Eine didemnin verbindung enthaltende pharmazeutische formulierung

Info

Publication number
ATE217532T1
ATE217532T1 AT99905091T AT99905091T ATE217532T1 AT E217532 T1 ATE217532 T1 AT E217532T1 AT 99905091 T AT99905091 T AT 99905091T AT 99905091 T AT99905091 T AT 99905091T AT E217532 T1 ATE217532 T1 AT E217532T1
Authority
AT
Austria
Prior art keywords
compound
didemnine
pharmaceutical formulation
formulation containing
didemnin
Prior art date
Application number
AT99905091T
Other languages
English (en)
Inventor
Jacob Hendrik Beijnen
Bastiaan Nuyen
Roland E C Henrar
Andres Pharma Mar Sa Gomez
Jose Jimeno
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE217532(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE217532T1 publication Critical patent/ATE217532T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99905091T 1998-02-18 1999-02-18 Eine didemnin verbindung enthaltende pharmazeutische formulierung ATE217532T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803448.1A GB9803448D0 (en) 1998-02-18 1998-02-18 Pharmaceutical formulation
PCT/GB1999/000511 WO1999042125A1 (en) 1998-02-18 1999-02-18 Pharmaceutical formulation of a didemnin compound

Publications (1)

Publication Number Publication Date
ATE217532T1 true ATE217532T1 (de) 2002-06-15

Family

ID=10827213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905091T ATE217532T1 (de) 1998-02-18 1999-02-18 Eine didemnin verbindung enthaltende pharmazeutische formulierung

Country Status (16)

Country Link
US (1) US8420130B1 (de)
EP (1) EP1054686B1 (de)
JP (2) JP4536255B2 (de)
KR (1) KR100595597B1 (de)
CN (1) CN1170586C (de)
AT (1) ATE217532T1 (de)
AU (1) AU754073B2 (de)
BR (1) BRPI9908088C1 (de)
CA (1) CA2321116C (de)
DE (1) DE69901487T2 (de)
DK (1) DK1054686T3 (de)
ES (1) ES2175940T3 (de)
GB (1) GB9803448D0 (de)
IL (1) IL137911A (de)
PT (1) PT1054686E (de)
WO (1) WO1999042125A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
DE10008128A1 (de) * 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
EP1620117A4 (de) 2003-03-12 2009-07-29 Pharma Mar Sa Verbesserte antitumorale behandlungen
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN100335495C (zh) * 2006-01-23 2007-09-05 南方医科大学 一种海鞘多肽及其制备方法
WO2007101235A2 (en) 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP6125436B2 (ja) * 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
US20230158102A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
CN115461067A (zh) 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
AU2021231521A1 (en) 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus
CN114085272B (zh) * 2022-01-10 2022-06-10 中山大学 一种isaridin类环酯肽衍生物及其制备方法和应用
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
JPS5781413A (en) * 1980-09-12 1982-05-21 Univ Illinois Didemnin antibiotic
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
ES2151277T3 (es) 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
EP0918693B1 (de) 1996-07-03 2001-11-07 C G Paxton Limited Behälter
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
US6380156B1 (en) 1996-10-24 2002-04-30 The Board Of Trustees Of The University Of Illnois Total synthesis of the amino hip analogue of didemnin A
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CZ302498B6 (cs) 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
MXPA03003230A (es) 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
DE60229414D1 (de) 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
EP1620117A4 (de) 2003-03-12 2009-07-29 Pharma Mar Sa Verbesserte antitumorale behandlungen

Also Published As

Publication number Publication date
US8420130B1 (en) 2013-04-16
KR100595597B1 (ko) 2006-07-03
EP1054686A1 (de) 2000-11-29
WO1999042125A1 (en) 1999-08-26
CN1170586C (zh) 2004-10-13
PT1054686E (pt) 2002-09-30
CA2321116C (en) 2009-10-06
BRPI9908088B8 (pt) 2017-03-07
BR9908088B1 (pt) 2013-05-21
DE69901487T2 (de) 2002-12-19
JP2002503704A (ja) 2002-02-05
ES2175940T3 (es) 2002-11-16
AU2538999A (en) 1999-09-06
JP2010163443A (ja) 2010-07-29
IL137911A (en) 2006-04-10
CA2321116A1 (en) 1999-08-26
EP1054686B1 (de) 2002-05-15
IL137911A0 (en) 2001-10-31
KR20010040993A (ko) 2001-05-15
BRPI9908088C1 (pt) 2021-05-25
JP4536255B2 (ja) 2010-09-01
DE69901487D1 (de) 2002-06-20
BR9908088A (pt) 2000-10-31
AU754073B2 (en) 2002-11-07
HK1032538A1 (en) 2001-07-27
GB9803448D0 (en) 1998-04-15
CN1330551A (zh) 2002-01-09
DK1054686T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
DE69901487D1 (de) Eine didemnin verbindung enthaltende pharmazeutische formulierung
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
NO974618L (no) Farmasöytiske preparater for intranasal administrasjon
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
CA2126091A1 (fr) Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE223232T1 (de) Tocopherolzusammensetzungen zur abgabe von biologisch aktiven substanzen
NO901116D0 (no) Beleggmateriale som regulerer legemiddelfrigjoerelse fra preparater med langvarig virkning.
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
DE59811768D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine
NO20010537D0 (no) Farmasöytiske preparater omfattende ibuprofen og domperidon
PT1186292E (pt) Preparados solidos com estrutura multinuclear
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
DE69940708D1 (de) Pharmazeutische Zubereitungen zur parenteralen Verabreichung enthaltend Epothilon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification